Navigation Links
Johnson & Johnson to Host Analyst Conference Call To Review Six-Month Trial Results From NEVO RES I
Date:5/12/2009

NEW BRUNSWICK, N.J., May 12 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at noon (Eastern Time) on Tuesday, May 19, 2009 to review the primary data from NEVO RES I, the pivotal European trial of the NEVO(TM) Sirolimus-eluting Coronary Stent.

NEVO(TM) is the first and only drug-eluting stent utilizing a unique reservoir (RES) technology. Results from this trial will support a design dossier submission for CE Mark approval in Europe and in other countries that accept CE mark designation.

Seth Fischer, Company Group Chairman, Worldwide Franchise Chairman, Cordis; Campbell Rogers, MD, Chief Scientific Officer and Global Head, R&D, Cordis; and Stan Panasewicz, Director, Investor Relations, Johnson & Johnson, will host the call.

Investors and other interested parties may access the broadcast by visiting the Company's website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately two hours after the conference call concludes by visiting www.investor.jnj.com.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
7. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
8. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
9. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
10. UAN Mourns Passing of President Cheryl L. Johnson, RN
11. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... Casa Velas, an ... properties of precious stones to complement its new wellness suites . The two ... and feature a plethora of special services and insuite amenities, from a custom soap ...
(Date:5/25/2016)... , ... May 25, 2016 , ... America Walks ... Carol Reichbaum, M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public ... will enable Ms. Reichbaum and 24 other advocates from around the country to participate ...
(Date:5/25/2016)... ... 2016 , ... "FCPX LUT Intense allows users to cycle through different high-contrast ... CEO of Pixel Film Studios. , With the FCPX LUT Intense Plugin ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
(Date:5/25/2016)... ... May 25, 2016 , ... Consumer access to organic ... June 2016, Kashi®, a maker of whole grain cereals and other plant-based foods, will ... ingredient: hard red winter wheat processed by Hesco/Dakota Organic Products. , The transitional ...
(Date:5/25/2016)... New Jersey (PRWEB) , ... May 25, 2016 , ... ... specialized technology firm will be selling the device branded as Stern’s Real Time ... is geared to bedbugs to the hotel and motel industry, colleges for use in ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: